he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:高血压患儿死亡简析
下一页:系统性癫痫的先兆研究
- 2022-05-02拿什么挺身而出你 我的帕金森
- 2022-05-02医院管理者为何爱对症疗程?
- 2022-04-252013年国际抗癫痫理事会抗癫痫药使用指南
- 2022-04-21高血压患儿死亡简析
- 2016AAN:神经专家发表了有前途的专业见解
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 癫痫患者手术评估新型工具
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 特发性癫痫大发作药物治疗的首选
- 月经性癫痫患者妊娠期癫痫控制更好
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 上海率先探索异地就医门诊费直接结算
- 癫痫治疗 中医治疗癫痫不用担心
- 抗癫痫药物预防新发癫痫:任重而道远
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- Radiology:利用MR颞叶癫痫病灶内侧指纹识别评价的价值
- 癫痫定位新方法:无框架立体定向脑电图技术
- 癫痫治疗障碍仍难以克服
- 北京癫痫手术费用
- 癫痫症状 如何护理癫痫患者?
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 2013国际抗癫痫联合会抗癫痫药用指南
- 脑梗死的症状是什么有这些前兆要谨慎
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- Medpage Today:不同类型的抗癫痫药物更有利
- 癫痫猝死:凶手是谁?
- 心理百科:春节期间小心疾病
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 2015 神经系统疾病诊疗进展
- 常见的癫痫病因有哪些?
- 英国竞争监管机构控诉辉瑞公司发作药品价格过高
- 最近治疗癫痫病方法有什么
- 青少年癫痫病怎么治疗最再一
- 癫痫、抽搐大不同|及时外科手术,将疾病扼杀在早期发展阶段
- 早期癫痫的体现是什么 讲述癫痫疾病的症状
- 引发癫痫病的成因有什么
- 一种特异性的癫痫发作型式【视频】
- 治疗痉挛的费用是多少
- 小儿良性癫痫病有什么病因
- 癫痫病能治愈吗,先详细了解状况?
- 科技助力癫痫外科手术发展,LITT激光间质热疗微创外科手术难治性癫痫
- 治疗癫痫病比较好的工具是什么
- 哮喘的症状 睡觉中犯哮喘会有哪些表现
- 成年人病症有哪些病因